Overview

Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

Status:
Not yet recruiting
Trial end date:
2023-12-22
Target enrollment:
Participant gender:
Summary
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study will determine if a lower dose (5 millicuries) would suffice.
Phase:
Phase 2
Details
Lead Sponsor:
GE Healthcare
Collaborator:
Labcorp Drug Development Inc